Beam Therapeutics BEAM 深 滬
已收盤 08-07 16:00:00 美东时间
27.48
+0.230
+0.84%
華盛通- 最 高28.35
- 今 開27.71
- 成交量 132.43万股
- 最 低 27.13
- 昨 收 27.25
- 總市值 28.38亿
- 52周最高 38.26
- 市盈率 靜 --
- 換手率 1.28%
- 52周最低 15.60
- 委 比 -34.53%
- 總股本 1.03亿
- 歷史最高 138.522
- 量 比 0.86
- 振 幅 4.48%
- 歷史最低 13.00
- 每 手 1
- 風險率 4.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多财报速睇 | Beam Therapeutics 2026财年Q2营收0.00亿美元，同比下降94.2%；归母净利润亏损1.23亿美元，同比亏损扩大20.1%
华盛资讯8月4日讯，Beam Therapeutics公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比下降94.2%，归母净利润亏损1.23亿美元，同比亏损扩大20.1%。
08-04 19:41
财报速睇 | Beam Therapeutics 2026财年Q2营收0.00亿美元，同比下降94.2%；归母净利润亏损1.23亿美元，同比亏损扩大20.1%
华盛资讯8月4日讯，Beam Therapeutics公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比下降94.2%，归母净利润亏损1.23亿美元，同比亏损扩大20.1%。
08-04 19:35
Beam Therapeutics Q2 EPS $(1.18) Misses $(1.11) Estimate, Sales $490.000K Miss $16.370M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.11) by 6.31 percent. This is a 18 percent decrease over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $490.000 thous...
08-04 19:14
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics reported second quarter 2026 financial results and updates on its clinical programs. Key highlights include the initiation of the pivotal BEAM-302 trial for AATD, completion of dosing in the BEACON trial for risto-cel in SCD, and IND clearance for BEAM-304 in PKU. The company ended Q2 with $1.2 billion in cash, supporting operations into mid-2029.
08-04 11:00
Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD) at the European Respir...
07-23 19:02
ARK Invest snaps up $16.7M in SPCX shares, trims Deere exposure
Cathie Wood’s ARK Invest doubled down on its aerospace bet on Wednesday, snapping up 122,807 shares of Space Exploration Technologies Corp (SPCX) for $16.7 million across several of its exchange-trade...
07-16 16:50
美股大行评级 | 潜在涨幅215.37%！摩根士丹利上调TeraWulf(WULF)目标价至72美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从66.5美元升至72美元；HC Wainwright & Co.：维持Vera Therapeutics"买入"评级，目标价从110美元升至125美元
07-09 12:35
Prime Medicine gains after winning arbitration with Beam Therapeutics
Prime Medicine (PRME) added ~8% in the premarket on Wednesday after an arbitration tribunal sided with the gene editing company in connection with a previously disclosed dispute with its rival Beam Th...
07-08 21:05
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
Prime Medicine announced a favorable resolution of its arbitration with Beam Therapeutics, confirming its rights to develop and commercialize PM647 for Alpha-1 Antitrypsin Deficiency (AATD). The tribunal ruled that Prime Medicine did not breach the 2019 Collaboration and License Agreement, and no monetary damages are owed to Beam. PM647 uses Prime Medicine’s universal liver lipid nanoparticle (LNP) to correct the E342K mutation in the SERPINA1 ge...
07-08 12:00
